A pre-clinical stage medical device company, CytexOrtho designed its ReNew Hip implant to restore the joint naturally rather than replace it. It’s a potential solution for active people with early hip disease who are too young for a total hip replacement, according to AAOS.
CytexOrtho founder and CEO Bradley Estes explained during the pitch competition that surgeons remove only the damaged tissue, replacing it with the implant. The implant restores the joint to its proper form and contour. The implant slowly absorbs into the body while cells move into gaps in the implant’s layers and form functional tissue. The device has FDA Breakthrough Device designation. The company is completing a phase 1 clinical trial and is seeking funding to start a phase 2 trial.
Estes added: “Being named winner of the first OrthoPitch competition validates the hard work our team at CytexOrtho has devoted to helping patients through this technology. As we approach first-in-human clinical trials this year, we’re thrilled to receive this recognition from AAOS and are looking forward to promising outcomes.”
Presented by AAOS and sponsored by medical device consulting firm MCRA, OrthoPitch kicked off in July 2023 with a call for entries. The AAOS Devices, Biologics and Technology Committee conducted a multi-staged review process. The top four submissions — Biomedical Bonding AB, CytexOrtho, nView medical and Solenic Medical — pitched their concepts live to a panel of regulatory, reimbursement and commercialization experts, physicians and investors at the AAOS annual meeting in San Francisco this week. CytexOrtho won in a live online vote.
